Transforming The DMTA Cycle Through Enhanced Collaboration

Dr Robert Scoffin is an experienced entrepreneur and senior executive within the life sciences software industry. Rob joined Cresset as CEO in 2010 and now also serves as Chairman of Cresset. During the time he has been leading the team, Cresset has further developed its software and contract research divisions from a very solid customer base into a high-growth and profitable business. Rob also serves as co-Chairman for Torx Software, a collaboration between Cresset and Elixir Software.

Dr Stevan Djuric, now President of a Medicinal Chemistry Consulting company, is a highly experienced leader within the pharmaceutical sector. Previously, he held the role of Vice President, Discovery Chemistry and Technology at AbbVie. Here he was also head of their global Medicinal Chemistry Leadership Team and responsible for the Discovery Chemistry and Technology organization. In recognition of his scientific achievement, he was named an AbbVie Distinguished Research Fellow in 2015 (the highest level of scientific achievement in the company.)

Dr Lewis Vidler is a Senior Director of Structure Based Drug Design at Eli Lilly. He achieved a first-class chemistry degree at the University of Oxford in 2009 and subsequently completed his PhD in Computational Medicinal Chemistry at the Institute of Cancer research in London in 2013. He joined Lilly later that year and spent an initial duration of 7 years there, during which he progressed to Senior Research Scientist. Following shorter stints as a computational chemist at UCB and Amphista Therapeutics, he returned back to Eli Lilly again earlier this year, to further progress his career.

Lewis currently serves as VP of Research at Acelot, where he specializes in Computational Discovery of small molecules for neurological conditions. He trained as a chemist at the University of St. Andrews & specialized in theoretical chemistry at the University of Southampton before taking up an industrial postdoctoral position at Novartis' former respiratory diseases research site in the UK. Subsequently moving to a position at Novartis in the US, he established the footprint of computational chemistry in the organization and contributed significantly to the development of small molecules leading to clinical entry & eventual FDA approval.

Dr Sabine Ruppel is an accomplished and results-focused drug hunter with 20+ years of experience within small-molecule drug discovery and pre-clinical development. Now holding the role of VP for Discovery Research, she leads the multi-disciplinary discovery team, comprised of medicinal chemistry, DMPK, structural research, biochemistry/ biophysics, and computational chemistry roles. Sabine has also previously worked with external teams of up to 40 CRO chemists, and prides herself on her ability to deliver timely results, while fostering an inclusive environment in support of developing creative solutions to multi-dimensional challenges.